Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology

Aldona Mularczyk; Maciej Gonciarz; Witold Bartnik; Marek Durlik; Piotr Eder; Anita Gąsiorowska; Krzysztof Linke; Michał Łodyga; Liliana Łykowska-Szuber; Ewa Małecka-Panas; Magdalena Pawlik; Piotr Radwan; Grażyna Rydzewska

doi:10.5114/pg.2014.40842

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla gastroenterologów!

www.egastroenterologia.pl

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

1/2014
vol. 9

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Artykuł specjalny

Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology

Aldona Mularczyk

,

Maciej Gonciarz

,

Witold Bartnik

,

Marek Durlik

,

Piotr Eder

,

Anita Gąsiorowska

,

Krzysztof Linke

,

Michał Łodyga

,

Liliana Łykowska-Szuber

,

Ewa Małecka-Panas

,

Magdalena Pawlik

,

Piotr Radwan

,

Grażyna Rydzewska

Prz Gastroenterol 2014; 9 (1): 1–3

DOI: https://doi.org/10.5114/pg.2014.40842

Data publikacji online: 2014/03/01

Pełna treść artykułu Pobierz cytowanie

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Mularczyk A, Gonciarz M, Bartnik W, et al. Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Gastroenterology Review/Przegląd Gastroenterologiczny. 2014;9(1):1-3. doi:10.5114/pg.2014.40842.

APA

Mularczyk, A., Gonciarz, M., Bartnik, W., Durlik, M., Eder, P.,  & Gąsiorowska, A. et al. (2014). Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Gastroenterology Review/Przegląd Gastroenterologiczny, 9(1), 1-3. https://doi.org/10.5114/pg.2014.40842

Chicago

Mularczyk, Aldona, Maciej Gonciarz, Witold Bartnik, Marek Durlik, Piotr Eder, Anita Gąsiorowska,  and Krzysztof Linke et al. 2014. "Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology". Gastroenterology Review/Przegląd Gastroenterologiczny 9 (1): 1-3. doi:10.5114/pg.2014.40842.

Harvard

Mularczyk, A., Gonciarz, M., Bartnik, W., Durlik, M., Eder, P., Gąsiorowska, A., Linke, K., Łodyga, M., Łykowska-Szuber, L., Małecka-Panas, E., Pawlik, M., Radwan, P.,  and Rydzewska, G. (2014). Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Gastroenterology Review/Przegląd Gastroenterologiczny, 9(1), pp.1-3. https://doi.org/10.5114/pg.2014.40842

MLA

Mularczyk, Aldona et al. "Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 9, no. 1, 2014, pp. 1-3. doi:10.5114/pg.2014.40842.

Vancouver

Mularczyk A, Gonciarz M, Bartnik W, Durlik M, Eder P, Gąsiorowska A et al. Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Gastroenterology Review/Przegląd Gastroenterologiczny. 2014;9(1):1-3. doi:10.5114/pg.2014.40842.

Metryki PlumX:

Biological medical products are drugs whose active components are produced only by living, genetically modified organisms or live cell cultures. Patents and exclusivity for most biopharmaceuticals has either expired or will expire soon, which enables biotechnological companies to introduce similar biological products. The problem of replacing a biological medicine with a biosimilar in the course of therapy remains open. In this statement, the Working Group of the Polish National Consultant in Gastroenterology, in the absence of data regarding bioequivalence in patients with inflammatory bowel disease, does not recommend switching from original biological medicine to its biosimilar analogue in the course of treatment in inflammatory disease patients; however, this may change after receiving the results of controlled studies regarding bioequivalence in this group.

słowa kluczowe:

Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology

Aldona Mularczyk , Maciej Gonciarz , Witold Bartnik , Marek Durlik , Piotr Eder , Anita Gąsiorowska , Krzysztof Linke , Michał Łodyga , Liliana Łykowska-Szuber , Ewa Małecka-Panas , Magdalena Pawlik , Piotr Radwan , Grażyna Rydzewska

biosimilar medicines, inflammatory bowel disease

Aldona Mularczyk

,

Maciej Gonciarz

,

Witold Bartnik

,

Marek Durlik

,

Piotr Eder

,

Anita Gąsiorowska

,

Krzysztof Linke

,

Michał Łodyga

,

Liliana Łykowska-Szuber

,

Ewa Małecka-Panas

,

Magdalena Pawlik

,

Piotr Radwan

,

Grażyna Rydzewska